Leading specialty drug manufacturer to advance compliance, oversight, and inspection readiness with Veeva Vault QualityDocs and Veeva Vault Training
BARCELONA, Spain, July 25, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Neuraxpharm will use Veeva Vault QualityDocs and Veeva Vault Training to advance its quality operations. Veeva quality applications will help Neuraxpharm achieve greater oversight and inspection readiness, while improving collaboration across its network of over 100 contract development and manufacturing organizations (CDMOs).
“Veeva Vault Quality enables Neuraxpharm to bring GxP documentation and quality training onto one platform making quality operations more efficient and scalable,” said Susanne Cater, head of corporate quality at Neuraxpharm. “With Veeva Vault QualityDocs and Veeva Vault Training, we can advance quality document management and compliance, including how we work with CDMOs.”
Neuraxpharm is a pharmaceutical leader in disorders affecting the central nervous system (CNS). Vault QualityDocs supports efficient GxP content management and information sharing across its sites, while Vault Training enables Neuraxpharm to deploy training and curricula to help ensure GxP compliance.
“With Veeva Vault Quality, Neuraxpharm can streamline content and training, enabling the company to scale as it expands its product portfolio,” said Sofia Lange, director of quality strategy for Europe at Veeva. “We’re excited to partner with Neuraxpharm in advancing quality across its organization and keep production of vital CNS treatments for patients on track.”
Additional InformationFor more on Veeva Vault Quality, visit: veeva.com/eu/VaultQuality
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 35 and 36), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy Whittaker
Veeva Systems
+49-695-095-5486
[email protected]
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
